Business
KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about
About this update from Kala Bio, Inc.
[{"type":"image","alt":"KALA BIO, Inc.","displaySize":"","headline":null,"caption":"KALA BIO, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":210,"url":"https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/poFKt69Bd.mweg6BAiQGYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI5NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5317c130ba58e5fbeca603a90c5b4c46","width":300,"height":210}},"lazy":false},{"type":"text","content":"ARLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced that it has entered into definitive agreements for the purchase of an aggregate of 10,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.00 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 5, 2025, subject to the satisfaction of customary closing conditions.","length":578,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","length":86,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to repay certain of its indebtedness and for general corporate purposes.","length":346,"tagName":"p"},{"type":"text","content":"The securities described above are being offered pursuant to a “shelf” registration statement (File No. 333-270263) filed with the Securities and Exchange Commission (“SEC”) on March 3, 2023 and declared effective on May 11, 2023. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to the securities being offered will be filed with the SEC and be available at the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the securities being o...